14154 Federal Register / Vol. 62, No. 57 / Tuesday, March 25, 1997 / Notices

agencies to monitor the implementation

of Presidential Executive Orders.

D. Division of Policy and Planning

proposes and implements national

policy on the CSE program and provides

policy guidance and interpretations to

states in developing and operating their

programs according to federal law. It

develops legislative proposals and

regulations to implement new

legislation, court decisions or directives

from higher authority. The Division

develops procedures for review and

approval of state plans by the OCSE

regional offices. It develops and

monitors research, interstate, and other

demonstration and evaluation studies

and publishes program statistics. The

Division is also responsible for strategic

planning and performance

measurements and standards

development. It prepares legislative cost

estimates and is responsible for national

child support budget formulation.

E. Division of Consumer Services

provides direction and leadership for a

variety of consumer affairs activities in

support of the nationwide child support

enforcement program. Provides advice

on strategies and approaches to be used

to improve public understanding of and

access to OCSE programs and policies.

Develops and publishes informational

materials. Promotes ‘‘best’’ child

support practices to the public through

monthly publication of the Child

Support Report. Advises the Director

and Deputy Director, OCSE of the

impact of child support enforcement

policy and program upon consumers

and provides a focal point for

intergovernmental and consumer

relations and consultation. The Division

is also responsible for operation of the

OCSE Homepage on the internet and

insuring that the information is placed

thereon in a timely manner.

F. Division of State and Local

Assistance, in concert with regional

offices, provides information and

assistance on Child Support

Enforcement state operations. It

provides national direction and

leadership for training and technical

assistance activities to increase Child

Support Enforcement (CSE) program

effectiveness both at Federal and State

levels; develops guides and resource

materials and serves as a clearinghouse

for specialized program techniques for

use by ACF regional offices and States;

and ensures transfer of best practices

among State and local CSE enforcement

agencies. The Division, in consultation

with the Division of Consumer Services,

develops informational materials and

operates a national CSE training center;

provides logistical support for both

training events and meetings; and

monitors contracts with organizations

affiliated with child support

enforcement programs in the areas of

training and technical assistance. The

Division provides outreach and liaison

services to a variety of special interest

populations concerning establishment

of paternity and collection of child

support.

Dated: March 18, 1997.

Olivia A. Golden,

Principal Deputy Assistant Secretary for

Children and Families.

[FR Doc. 97–7521 Filed 3–24–97; 8:45 am]

BILLING CODE 4184–01–P

Food and Drug Administration

[Docket No. 91G–0495]

Cerestar USA, Inc., and Roquette

America, Inc.; Withdrawal of GRAS

Affirmation Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

withdrawal, without prejudice to a

future filing, of a petition (GRASP

1G0376) proposing that β-cyclodextrin

be affirmed as generally recognized as

safe (GRAS) for use as a formulation aid

in the production of dry flavoring mixes

for preparation of cocktail-type

alcoholic beverages.

FOR FURTHER INFORMATION CONTACT:

Andrew D. Laumbach, Center for Food

Safety and Applied Nutrition (HFS–

215), Food and Drug Administration,

200 C St. SW., Washington, DC 20204,

202–418–3071.

SUPPLEMENTARY INFORMATION: In a notice

published in the Federal Register of

February 3, 1992 (57 FR 4043), FDA

announced that a petition (GRASP

1G0376) had been filed by the law

offices of Keller and Heckman, 1001 G

St. NW., suite 500 West, Washington,

DC 20001, on behalf of Cerestar USA,

Inc. (formerly, American MaizeProducts Co.), 1100 Indianapolis Blvd.,

Hammond, IN 46320–1094, and

Roquette America, Inc. (formerly,

Roquette Corp.), 1550 Northwestern

Ave., Gurnee, IL 60031–2392. The

petition proposed that β-cyclodextrin be

affirmed as GRAS for use as a

formulation aid in the production of dry

flavoring mixes for the preparation of

cocktail-type alcoholic beverages.

Recently, the petitioners submitted

another petition (GRASP 6G0421) that

requests GRAS affirmation of βcyclodextrin for use as a flavor

protectant in human food. The filing of

this petition was announced in a notice

that published in the Federal Register of

September 20, 1996 (61 FR 49472). The

general use in food that is proposed in

petition GRASP 6G0421 encompasses

the limited use presently proposed in

GRASP 1G0376. Accordingly, the

petitioners have requested the

withdrawal of GRASP 1G0376. Cerestar

USA, Inc., and Roquette America, Inc.,

have now withdrawn the petition

without prejudice to a future filing (21

CFR 171.7).

Dated: February 27, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval,

Center for Food Safety and Applied Nutrition.

[FR Doc. 97–7479 Filed 3–24–97; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 97M–0084]

VISX, Inc.; Premarket Approval of VISX

Excimer Laser System (Models B and

C) for Photorefractive Keratectomy

(PRK)

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing its

approval of the application by VISX,

Inc., Santa Clara, CA, for premarket

approval, under the Federal Food, Drug,

and Cosmetic Act (the act), of the VISX

Excimer Laser System (Models B and C)

for PRK. After reviewing the

recommendation of the Ophthalmic

Devices Panel, FDA’s Center for Devices

and Radiological Health (CDRH)

notified the applicant, by letter of March

27, 1996, of the approval of the

application.

DATES: Petitions for administrative

review by April 24, 1997.

ADDRESSES: Written requests for copies

of the summary of safety and

effectiveness data and petitions for

administrative review to the Dockets

Management Branch (HFA–305), Food

and Drug Administration, 12420

Parklawn Dr., rm. 1–23, Rockville, MD

20857.

FOR FURTHER INFORMATION CONTACT: Jan

C. Callaway, Center for Devices and

Radiological Health (HFZ–460), Food

and Drug Administration, 9200

Corporate Blvd., Rockville, MD 20850,

301–594–2018.

SUPPLEMENTARY INFORMATION: On June

15, 1996, VISX, Inc., Santa Clara, CA

95051, submitted to CDRH an

application for premarket approval of

the VISX Excimer Laser System (Models

B and C). The device is an argon